1stOncology™: Cancer Intelligence Service – Page 14400 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

BioClin Therapeutics, Inc.Announces Poster Presentation of
B-701at the 2018 American Society of Clinical Oncology
(ASCO) Annual Meeting

On May 17, 2018 BioClin Therapeutics, Inc., a clinical stage drug development company reported that data will be presented from its ongoing Phase 1b/2 study of B-701, a first-in-class anti-fibroblast growth factor receptor 3 (FGFR3) monoclonal antibody, plus docetaxel for metastatic bladder cancer at a poster session at the 2018 American Society for Clinical Oncology (ASCO) (Free ASCO Whitepaper) meeting being held June 1-5, 2018 in Chicago, IL (Press release, BioClin Therapeutics, MAY 17, 2018, View Source [SID1234526785]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The details of the poster presentation are as follows:

[Abstract 4534]
FIERCE-21: Phase 1b/2 study of Docetaxel + B-701, a Selective Inhibitor of FGFR3, in Relapsed or Refractory (R/R) Metastatic Urothelial Carcinoma (mUCC).

Joaquim Bellmunt, M.D., Ph.D., Dana-Farber Cancer Institute
Session: Genitourinary (Nonprostate) Cancer
Poster Session Date/Time: Saturday, June 3, 2018, 8:00 – 11:30 a.m., CDT, Hall A

Tarveda Therapeutics to Present Data from Phase 1 Study of PEN-221 at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting

On May 17, 2018 Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing Pentarins as a new class of potent and selective cancer medicines, reported that it will present Phase 1 results from a Phase 1/2a study of PEN-221 in patients with neuroendocrine tumors or small cell lung cancer at the 2018 American Society for Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting occurring June 1-5, 2018 in Chicago IL (Press release, Tarveda Therapeutics, MAY 17, 2018, View Source [SID1234526784]).

The data presented will describe the safety, tolerability, pharmacokinetics, and preliminary efficacy of PEN-221, a miniature drug conjugate containing a peptide ligand that is highly selective in targeting the somatostatin receptor 2 (SSTR2) that is conjugated to the potent payload DM1. SSTR2 is a cell surface target that is overexpressed in a variety of solid tumor cancers. PEN-221 is currently being evaluated in a Phase 2a trial in patients with gastrointestinal midgut neuroendocrine tumors, pancreatic neuroendocrine tumors, or small cell lung cancer.

"We are very pleased to have completed the Phase 1 portion of our Phase 1/2a clinical trial for PEN-221 on schedule and to present the data from the Phase 1 trial evaluating PEN-221 at ASCO (Free ASCO Whitepaper)," said Drew Fromkin, President and Chief Executive Officer of Tarveda. "We are encouraged by the data from studies of PEN-221 to date and look forward to advancing the Phase 2a portion of the study for PEN-221 as well as our Phase 1 trial for PEN-866."

Details of the poster presentation are as follows:

Title: First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): Phase 1 results.
Abstract Number: 4097
Date: June 3, 2018
Time: 8:00 – 11:30 AM CT
Location: Hall A

About Pentarins
Tarveda is developing Pentarins, potent and selective miniature drug conjugates with high affinity for specific cell surface and intracellular targets. Pentarins are engineered to bind to their tumor cell targets and provide sustained release of their potent therapeutic payloads deep into solid tumor tissue. Comprised of a targeting ligand conjugated to a potent cancer cell killing agent through a tuned chemical linker, Pentarins are designed to overcome the deficits of both larger antibody drug conjugates and small molecules that limit their therapeutic effectiveness against solid tumors. Together, the components of Tarveda’s Pentarins have distinct, yet synergistic, anticancer attributes: the small size of Pentarins allows for rapid and deep penetration into the tumor tissue, the ligand’s targeting ability allows for specific binding and retention in tumor cells, and the chemical linker is tuned to optimize the release of the potent, cell killing payload inside the cancer cells for efficacy.

Flatiron Health Announces Research to Be Presented at American Society of Clinical Oncology 2018 Annual Meeting

On May 17, 2018 Flatiron Health reported 11 abstracts accepted for presentation at the 2018 American Society for Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, which will be held June 1-5 in Chicago (Press release, Flatiron Health, MAY 17, 2018, View Source [SID1234526783]). The research, spanning multiple tumor types and areas of study, utilized Flatiron’s highly-curated, nationally-representative, real-world oncology datasets, the largest in the United States.

The research to be presented includes collaborations with the Abramson Cancer Center of the University of Pennsylvania, Fred Hutchinson Cancer Research Center, Genentech (a member of the Roche Group), Huntsman Cancer Institute at the University of Utah, the National Cancer Institute, Roche, the U.S. Food & Drug Administration, and Yale Cancer Center.

The presentation schedule and links to abstracts can be found below. To learn more about Flatiron Health, visit our booth #2049 during the conference or click here.

Oral Presentation

Application of a real-world endpoint to identify and characterize genetic profiles of patients (pts) with poor prognosis in advanced non-small-cell lung cancer (aNSCLC)

Presenting Author: Greg Riely (Memorial Sloan Kettering Cancer Center)
Date/Time: 6/5/2018, 10:00 – 10:12 AM
Abstract: #12006
Location: S406
Session: Tumor Biology

Poster Discussion Presentation

Cost-effectiveness of multi-gene panel sequencing (MGPS) for advanced non-small cell lung cancer (aNSCLC) patients

Presenting Author: Lotte Steuten (Fred Hutchinson Cancer Research Center)
Date/Time: 6/2/2018, 4:45 – 6:00 PM
Abstract: #6513
Poster: #339
Location: S102
Session: Health Services Research, Clinical Informatics, and Quality of Care

Poster Presentations (Location: Hall A)

Real-world (RW) characteristics, treatment (tx) patterns, and overall survival (OS) in US patients (pts) with metastatic breast cancer (mBC) and CNS metastases (CNS mets)

Presenting Author: Ashwini Shewade (Genentech, a member of the Roche Group)
Date/Time: 6/2/2018, 8:00 – 11:30 AM
Abstract: #1037
Poster: #118
Session: Breast Cancer—Metastatic

Diffusion of innovation in oncology: A case study of immuno-oncology (IO) adoption for advanced non-small lung cancer (aNSCLC) patients across practices in the US

Presenting Author: Carrie Bennette (Flatiron Health)
Date/Time: 6/2/2018, 1:15 – 4:45 PM
Abstract: #6537
Poster: #363
Session: Health Services Research, Clinical Informatics, and Quality of Care

Association of baseline body mass index (BMI) with overall survival (OS) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) treated with nivolumab (N) and pembrolizumab (P)

Presenting Author: Jizu Zhi (U.S. Food & Drug Administration)
Date/Time: 6/2/2018, 1:15 – 4:45 PM
Abstract: #6553
Poster: #379
Session: Health Services Research, Clinical Informatics, and Quality of Care

Development of a dashboard for end-of-life care at an academic hospital

Presenting Author: Kerin Adelson (Yale Cancer Center)
Date/Time: 6/2/2018, 1:15 PM – 4:45 PM
Abstract: #6590
Poster: #415
Session: Health Services Research, Clinical Informatics, and Quality of Care

Real-world data (RWD) on tumor response (rwTR) in advanced non-small cell lung cancer (aNSCLC) patients receiving cancer immunotherapy and targeted therapies

Presenting Author: Michael W Lu (Genentech, a member of the Roche Group)
Date/Time: 6/2/2018, 1:15 – 4:45 PM
Abstract: #6578
Poster: #403
Session: Health Services Research, Clinical Informatics, and Quality of Care

Comparative effectiveness of carboplatin-pemetrexed (carbo-pem) with vs without bevacizumab (bev) in patients with advanced non-squamous (sq) non-small cell lung cancer (NSCLC)

Presenting Author: Stephen Bagley (Abramson Cancer Center of the University of Pennsylvania)
Date/Time: 6/3/18, 8:00 – 11:30 AM
Abstract: #9073
Poster: #396
Session: Lung Cancer—Non-Small Cell Metastatic

Age-related real-world outcomes for patients (pts) with metastatic colorectal cancer (mCRC)

Presenting Author: Rebecca Miksad (Flatiron Health)
Date/Time: 6/3/2018, 8:00 – 11:30 AM
Abstract: #3613
Poster: #106
Session: Gastrointestinal (Colorectal) Cancer

Immune checkpoint inhibitor (ICI) treatment in advanced melanoma (aMel) patients (pts) with hepatic or renal dysfunction (dysf): Real-world patient characteristics and outcomes

Presenting Author: Susan Spillane (National Cancer Institute)
Date/Time: 6/4/2018, 1:15 – 4:45 PM
Abstract: #9569
Poster: #396
Session: Melanoma/Skin Cancers

Risk stratification using patient-reported outcomes (PROs) in patients (pts) with advanced cancer

Presenting Author: Shiven Patel (Huntsman Cancer Institute at the University of Utah)
Date/Time: 6/4/2018, 1:15 – 4:45 PM
Abstract: #10101
Poster: #89
Session: Patient and Survivor Care

Cellerant Therapeutics, Inc. to Present Results of Phase 2 Clinical Trial of CLT-008 at American Society of Clinical Oncology (ASCO) 2018 Annual Meeting and European Hematology Association (EHA) 23rd Congress

On May 17, 2018 Cellerant Therapeutics, Inc., a clinical-stage company developing innovative immunotherapies for hematologic malignancies and other blood-related disorders, reported that investigators from Cellerant’s recently completed Phase 2 clinical trial of CLT-008 (romyelocel-L, human myeloid progenitor cells) will present key study results at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2018 Annual Meeting in Chicago, June 1-5, 2018, and at the 23rd Congress of the European Hematology Association (EHA) (Free EHA Whitepaper) in Stockholm, June 14-17, 2018 (Press release, Cellerant Therapeutics, MAY 17, 2018, View Source [SID1234526782]).

Tweet this
Cellerant is developing CLT-008, a universal, off-the-shelf cell therapy intended to prevent infections during neutropenia. Neutropenia is a serious side effect of myelosuppressive chemotherapy that leaves patients at high risk of serious, potentially life-threatening infections, leading to prolonged hospitalization and often reduced or delayed treatment doses. The Company conducted a randomized, controlled Phase 2 study of CLT-008 in patients newly diagnosed with acute myeloid leukemia (AML) who received induction chemotherapy.

"AML patients who undergo induction chemotherapy suffer severe and prolonged neutropenia, and the results from this study show significantly reduced infections in the CLT-008 group relative to control," said Ram Mandalam, Ph.D., CEO of Cellerant Therapeutics. "This product addresses a serious unmet need in AML patients. We are excited to present the study results at these two important medical meetings, and look forward to advancing CLT-008 to a Phase 3 study."

Presentation details are as follows:

ASCO Abstract #7043: Abboud, et al., A randomized controlled open label exploratory trial of CLT-008 myeloid progenitor cells (MPC) to decrease infections during induction for AML. Poster discussion on June 4, 2018, 8:00-11:30am CDT. Presenting author: Farhad Ravandi, M.D., Janiece and Stephen A. Lasher Professor of Medicine, University of Texas MD Anderson Cancer Center.

EHA Abstract #1405: Desai, et al., Decreased incidence of infection, use of antibacterials and days in hospital after administration of CLT-008 myeloid progenitor cells to subjects receiving AML induction therapy: Phase 2 Study Results. Oral presentation on June 16, 2018, 4:45-5:00pm CEST. Presenting author: Pinkal Desai, M.D., M.P.H., Assistant Professor of Medicine, Weill Cornell Medicine, New York.

TP Therapeutics Announces Phase 1 Data of Ropotrectinib (TPX-0005) to be Presented at the Annual American Society of Clinical Oncology Meeting

On May 17, 2018 TP Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing oncology therapies with a focus on addressing current drug resistance, reported that the Phase 1 data from the ongoing TRIDENT-1 Study of Ropotrectinib (TPX-0005) has been accepted for poster presentation and discussion on June 4 at the upcoming American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago, Illinois (Press release, TP Therapeutics, MAY 17, 2018, View Source [SID1234526781]).

TP Therapeutics Announces Phase 1 Data of Ropotrectinib (TPX-0005) to be Presented at the Annual American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Meeting

Tweet this
The presentation is entitled "A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor Ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1)".

The schedule for the poster display and discussion is as follows:

Poster Discussion
Time: 6/4/2018, 3:00 PM-4:15 PM

Title: A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor Ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1)
Abstract Number: 2513
Session Title: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Location: S406
Discussant: Valentina Boni, MD, PhD, START Madrid CIOCC Hospital Universitario Sanchinarro

Poster Display Information: Monday, June 4, 2018, 8:00-11:30 am
Location: Hall A
Lead author: Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center

About Ropotrectinib (TPX-0005)

Ropotrectinib (TPX-0005) is a potent and orally bioavailable investigational small molecule kinase inhibitor for ALK, ROS1, and TRK family. The clinical benefits of targeting ALK, ROS1, or TRK fusion kinase have been demonstrated with multiple kinase inhibitors already approved for the treatment of ALK+ non-small cell lung cancer (NSCLC), in addition to crizotinib for ROS1+ NSCLC, and larotrectinib and entrectinib in clinical studies for TRK+ cancers. The successes of these therapies are overshadowed by the development of acquired resistance. The acquired solvent front mutations including ALK G1202R, ROS1 G2032R, TRKA G595R and TRKC G623R render a common clinical resistance to the current ALK, ROS1, and TRK inhibitors. TPX-0005 is a potent kinase inhibitor against wildtype and mutated ALK, ROS1 and TRK family kinases, especially the clinically significant solvent front mutations, gatekeeper mutations, and emerging compound mutations after multiple line treatments. Ropotrectinib may provide new opportunities in the clinic to inhibit the abnormal signaling of ALK, ROS1, or TRK family in solid malignancies, and overcome resistance seen in refractory patients. TPX-0005 is currently being evaluated in a Phase 1/2, open-label, multi-center, first-in-human study of the safety, tolerability, pharmacokinetics and anti-tumor activity in patients with advanced solid tumors harboring ALK, ROS1, or NTRK1-3 rearrangements (TRIDENT-1, NCT03093116). For additional information about ropotrectinib trial, please refer to www.clinicaltrials.gov. Interested patients and physicians can also contact the TP Therapeutics Oncology Clinical Trial Hotline at 1-858-276-0005 or email [email protected].